問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Chi Mei Medical Center

  • 0

    Total Beds

  • 0

    Total Doctors

  • pidb_editor
  • 710Tainan CityTainan Yongkang

Recruiting Trial

145Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

421Cases

2012-10-02 - 2015-12-31

Phase III

A Randomized, Double-Blind, Placebo- and Active-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
11Sites

Terminated10Sites

Study ended1Sites

2017-08-01 - 2019-01-31

Phase III

A Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro, Both in Combination with Insulin Glargine or Insulin Degludec in Adults with Type 2 Diabetes PRONTO-T2D

  • Condition/Disease

    Type 2 Diabetes

  • Test Drug

    LY900014

Participate Sites
5Sites

Terminated5Sites

2017-08-01 - 2020-05-31

Phase III

Prospective, Randomized, Double-Blind Comparison of LY900014 to Insulin Lispro with an Open-Label Postprandial LY900014 Treatment Group, in Combination with Insulin Glargine or Insulin Degludec, in Adults with Type 1 Diabetes PRONTO-T1D.

  • Condition/Disease

    Type 1 Diabetes Mellitus

  • Test Drug

    LY900014

Participate Sites
6Sites

Terminated6Sites

歐弘毅
National Taiwan University Hospital

Division of Endocrinology

2017-07-01 - 2022-01-01

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study Followed by Long-Term Treatment for Evaluation of Efficacy and Safety of Baricitinib in Patients with Active Psoriatic Arthritis

  • Condition/Disease

    Psoriatic Arthritis

  • Test Drug

    Baricitinib (LY3009104)

Participate Sites
9Sites

Not yet recruiting8Sites

2016-02-01 - 2018-06-17

Phase III

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Migraine - the EVOLVE-2 Study

  • Condition/Disease

    Episodic Migraine

  • Test Drug

    LY2951742

Participate Sites
6Sites

Terminated6Sites

2013-12-01 - 2015-09-30

Phase III

A Prospective, Randomized, Open-Label Comparison of a Long-Acting Basal Insulin Analog LY2963016 to Lantus® in Adult Patients with Type 2 Diabetes Mellitus: The ELEMENT 4 Study

  • Condition/Disease

    Type II diabetes

  • Test Drug

    Insulin Basal Analog V (LY2963016)

Participate Sites
9Sites

Terminated9Sites

2020-01-01 - 2024-08-08

Phase III

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

  • Condition/Disease

    Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities

  • Test Drug

    Tirzepatide

Participate Sites
5Sites

Terminated5Sites

2019-02-15 - 2021-04-22

Phase III

Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    LY3298176

Participate Sites
9Sites

Terminated9Sites

2019-04-01 - 2022-12-15

Phase III

A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 versus Titrated Insulin Degludec on Glycemic Control in Patients with Type 2 Diabetes (SURPASS-3)

  • Condition/Disease

    Type 2 Diabetes Mellitus

  • Test Drug

    LY3298176

Participate Sites
9Sites

Terminated9Sites

2021-08-01 - 2028-01-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting4Sites

Recruiting3Sites

1 34 35 36 37 38 43
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB